The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study.

Trial Profile

The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Zotarolimus (Primary) ; ACE inhibitors; Angiotensin receptor antagonists; Anti-ischaemics; Antiplatelets; Beta-adrenergic receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors; Nitrates
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms BRAVE
  • Most Recent Events

    • 17 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top